Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for hepatitis C.

Mireen Friedrich-Rust1, Stefan Zeuzem, Christoph Sarrazin

  • 1Department of Internal Medicine, Saarland University Hospital, Kirrbergerstr., Bldg. 41, 66421 Homburg/Saar, Germany.

International Journal of Colorectal Disease
|September 22, 2005
PubMed
Summary

Early discontinuation of hepatitis C virus (HCV) treatment is recommended for genotype-1 patients who do not achieve a significant viral load reduction within 12 weeks. This strategy aims to optimize outcomes for chronic hepatitis C treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV Cure.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

[Hyperlipasemia following therapy with direct antiviral drugs in patients with chronic hepatitis C virus infection - data from the German Hepatitis C Registry (DHC-R)].

Zeitschrift fur Gastroenterologie·2026
Same author

[Core curriculum of intensive care and emergency medicine in internal medicine].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2025
Same author

Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapy.

Zeitschrift fur Gastroenterologie·2025
Same author

Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care.

Annals of hepatology·2025
Same author

Transjugular diagnostic procedures in hepatology: Indications, techniques and interpretation.

JHEP reports : innovation in hepatology·2025

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Pegylated interferon alfa and ribavirin is the standard therapy for chronic hepatitis C virus (HCV) infection.
  • Sustained virologic response rates range from 54-63% with current treatment durations of 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3.

Purpose of the Study:

  • To evaluate the efficacy of early treatment discontinuation for chronic hepatitis C virus (HCV) genotype-1 infected patients.
  • To determine criteria for optimizing HCV treatment duration based on viral kinetics.

Main Methods:

  • Analysis of sustained virologic response rates in genotype-1 HCV patients.
  • Assessment of HCV RNA concentration decline at 12 weeks of therapy.

Main Results:

Related Experiment Videos

  • Patients with genotype-1 HCV infection without a 2-log decline in HCV RNA concentration after 12 weeks have a very low probability (<1-2%) of sustained virologic response.
  • Early treatment discontinuation is indicated for these patients.

Conclusions:

  • Individualizing HCV therapy duration based on viral reduction kinetics can enhance sustained response rates.
  • Managing side-effects of interferon-based therapy is crucial for patient compliance and treatment success.
  • Development of direct antiviral drugs is expected to significantly expand future HCV treatment options.